Lundbeck Snaps Up Parkinson's Developer Prexton In Deal Worth €905m

 
• By Lucie Ellis-Taitt

Lundbeck has swooped in to buy Merck KGaA spinout Prexton Therapeutics for €100m upfront, prior to Phase II data readouts for its potential first-in-class Parkinson's drug, foliglurax.

Big Fish
Lundbeck acquires Prexton for novel Phase II Parkinson's disease drug • Source: Shutterstock

More from Deals

More from Business